Mitsubishi UFJ Securities’s BioMarin Pharmaceuticals BMRN Stock Holding History

Mitsubishi UFJ Securities’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-50	Closed	-$4K	–	17
2019 Q4	$4K	Hold	50	–	–	0.02%	78
2019 Q3	$3K	Hold	50	–	–	0.01%	86
2019 Q2	$4K	Hold	50	–	–	0.01%	202
2019 Q1	$4K	Hold	50	–	–	0.02%	129
2018 Q4	$4K	Hold	50	–	–	0.03%	95
2018 Q3	$5K	Hold	50	–	–	0.02%	192
2018 Q2	$5K	Hold	50	–	–	0.02%	188
2018 Q1	$4K	Hold	50	–	–	0.02%	204
2017 Q4	$4K	Hold	50	–	–	0.02%	203
2017 Q3	$5K	Hold	50	–	–	0.02%	187
2017 Q2	$5K	Hold	50	–	–	0.03%	184
2017 Q1	$4K	Hold	50	–	–	0.02%	197
2016 Q4	$4K	Hold	50	–	–	0.02%	210
2016 Q3	$5K	Hold	50	–	–	0.03%	192
2016 Q2	$4K	Hold	50	–	–	0.01%	221
2016 Q1	$4K	Hold	50	–	–	0.01%	190
2015 Q4	$5K	Hold	50	–	–	0.01%	240
2015 Q3	$5K	Hold	50	–	–	0.04%	214
2015 Q2	$7K	Hold	50	–	–	0.05%	221
2015 Q1	$6K	Buy	+50	New	+$5.3K	0.02%	229

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Mitsubishi UFJ Securities's BMRN Position: Q1 2020 in Review

Mitsubishi UFJ Securities sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2020, closing a stake of 50 shares — an estimated $4K sold.

Mitsubishi UFJ Securities first reported a position in BMRN in Q1 2015 and held it in 20 quarters. The position peaked at $7K in Q2 2015. 500 funds tracked by Wall St. Rank hold BMRN as of Q1 2020.

Mitsubishi UFJ Securities reported no remaining BioMarin Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
Mitsubishi UFJ Securities sold 50 BioMarin Pharmaceuticals shares in Q1 2020, an estimated $4K.
Mitsubishi UFJ Securities first reported a position in BioMarin Pharmaceuticals in Q1 2015 and held it in 20 quarters.
Mitsubishi UFJ Securities's BioMarin Pharmaceuticals position peaked at $7K in Q2 2015.
500 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2020.

Based on Mitsubishi UFJ Securities's 13F filing for Q1 2020, filed 13 May 2020.